SpringWorks Therapeutics to Discuss The ReNeu Topline Data Transcript
Good morning, ladies and gentlemen, and welcome to the SpringWorks Therapeutics conference call to discuss the Phase 2b ReNeu trial topline results. At this time, I would like to turn the call over to Samantha Sandler, Senior Director of Investor Relations.
Good morning, and thank you for joining us today for the ReNeu trial topline results call. Slides to accompany this conference call will be posted in the Investors & Media section of our website at www.springworkstx.com. And a recording of this webcast will also be made available on our website following this call.
Before we begin, I'd like to remind you that today's discussion will contain forward-looking statements that involve risks and uncertainties and that the company's actual results may differ materially from what is discussed during today's call. For a description of risk factors associated with investing in SpringWorks Therapeutics, please refer
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |